Direkt zum Inhalt
Merck

Fortfahren mit

1269447

USP

Fenofibrat

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

2-[4-(4-Chlorbenzoyl)-phenoxy]-2-methyl-propansäure-isopropylester

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern
PackungsgrößeSKUVerfügbarkeitPreis
200 mg
Warenkorb auf Verfügbarkeit prüfen
€ 407,00

Über diesen Artikel

Empirische Formel (Hill-System):
C20H21ClO4
CAS-Nummer:
Molekulargewicht:
360.83
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:

€ 407,00


Warenkorb auf Verfügbarkeit prüfen

Großbestellung anfragen
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten


grade

pharmaceutical primary standard

agency

USP

API family

fenofibrate

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2

InChI

1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3

InChI key

YMTINGFKWWXKFG-UHFFFAOYSA-N

Gene Information

human ... PPARA(5465)

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fenofibrate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Fenofibrate Capsules
  • Fenofibrate Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 1

Dieser Artikel
F0048000PHR12461269618
Fenofibrate United States Pharmacopeia (USP) Reference Standard

USP

1269447

Fenofibrate

Fenofibrate European Pharmacopoeia (EP) Reference Standard

F0048000

Fenofibrate

manufacturer/tradename

USP

manufacturer/tradename

EDQM

manufacturer/tradename

-

manufacturer/tradename

USP

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

certified reference material, pharmaceutical secondary standard

grade

pharmaceutical primary standard

format

neat

format

neat

format

neat

format

neat

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

API family

fenofibrate

API family

-

API family

fenofibrate

API family

fenofibrate

Gene Information

human ... PPARA(5465)

Gene Information

human ... PPARA(5465)

Gene Information

human ... PPARA(5465)

Gene Information

human ... PPARA(5465)


Still not finding the right product?

Explore all of our products under Fenofibrat


pictograms

Health hazard

signalword

Warning

hcodes

Hazard Classifications

STOT RE 2 Oral

target_organs

Liver

Lagerklasse

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable



Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen



Jonathan E Noonan et al.
Diabetes, 62(12), 3968-3975 (2013-11-23)
The drug fenofibrate has received major attention as a novel medical treatment for diabetic retinopathy (DR) and other diabetes-induced microvascular complications. This interest stems from two recent large, well-designed clinical trials that demonstrated large reductions in the progression of DR
Rafael Simó et al.
Current medicinal chemistry, 20(26), 3258-3266 (2013-06-12)
Despite improving standards of care, people with diabetes remain at risk of development and progression of diabetic retinopathy (DR) and visual impairment. Identifying novel therapeutic approaches, preferably targeting more than one pathogenic pathway in DR, and at an earlier stage
Samuel Rommelaere et al.
PloS one, 9(8), e104925-e104925 (2014-08-21)
Liver is a major regulator of lipid metabolism and adaptation to fasting, a process involving PPARalpha activation. We recently showed that the Vnn1 gene is a PPARalpha target gene in liver and that release of the Vanin-1 pantetheinase in serum



Global Trade Item Number

SKUGTIN
1269447-200MG04061838724540

Questions

Reviews

No rating value

Active Filters